Latest News
Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2
11 March 2026 - AcuraStem, a biotechnology company developing disease-modifying therapies for amyotrophic lateral sclerosis (ALS), announced on Tuesday that it has received a two-year research grant from non-profit organisation Target ALS to advance ...
Immunic granted European patent for vidofludimus calcium dosing regimens
...
Ascletis reports Phase II weight‑loss results for ASC30 depot formulation
...
Agenus triggers USD20m milestone payment under Zydus manufacturing collaboration
10 March 2026 - Immuno-oncology company Agenus Inc (Nasdaq:AGEN) said on Tuesday that it has triggered the first USD20m contingent payment under its strategic collaboration with Zydus Lifesciences Ltd.The payment was activated through contracted work...
HeartBeam and Mount Sinai partner to advance AI-enabled cardiac monitoring
10 March 2026 - Medical technology company HeartBeam Inc (NASDAQ:BEAT) on Tuesday announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the development and validation of next-generation AI-ECG ...